亚太药业：筹划公司控制权变更事项，股票自9月29日（星期一）开市起停牌

Group 1 - The core point of the article is that Asia Pacific Pharmaceutical (SZ 002370) announced a potential change in control, with its major shareholder, Ningbo Fubang Holding Group, and associated parties planning to negotiate the terms of the transaction [1] - The company has applied for a trading suspension starting September 29, 2025, to prevent abnormal stock price fluctuations during this uncertain period [1] - For the first half of 2025, the company's revenue composition shows that the pharmaceutical manufacturing sector accounted for 99.33% of total revenue, while other businesses contributed 0.67% [1] Group 2 - As of the report, Asia Pacific Pharmaceutical has a market capitalization of 4.2 billion yuan [2]